Results 51 to 60 of about 10,998,800 (355)

Reprogramming the immunosuppressive tumor microenvironment results in successful clearance of tumors resistant to radiation therapy and anti-PD-1/PD-L1

OncoImmunology, 2023
Despite breakthroughs in immune checkpoint inhibitors (ICI), the majority of tumors, including those poorly infiltrated by CD8+ T cells or heavily infiltrated by immunosuppressive immune effector cells, are unlikely to result in clinically meaningful ...
Debayan Mukherjee, Erminia Romano, Richard Walshaw, Leo A. H. Zeef, Antonia Banyard, Stephen J. Kitcatt, Eleanor J. Cheadle, Karoliina Tuomela, Swati Pendharkar, Aws Al-Deka, Beatrice Salerno, Sophie Raby, Ian G. Mills, Jamie Honeychurch, Tim M. Illidge   +14 more
doaj   +1 more source

Molecular pathogenesis and targeted therapy of sporadic pancreatic neuroendocrine tumors [PDF]

, 2015
Over the past few years, knowledge regarding the molecular pathology of sporadic pancreatic neuroendocrine tumors (PNETs) has increased substantially, and a number of targeted agents have been tested in clinical trials in this tumor type.
Ahn, Balogh, Bergers, Berruti, Capurso, Capurso, Carew, Castellano, Chamberlain, Chan, Chan, Chen, Clynes, Corbo, Corbo, Couvelard, De Wilde, Di Florio, Di Florio, Di Florio, Fazio, Fendrich, Gaur, Gurung, Han, Heaphy, Heaphy, Hobday, Hopfner, House, Jacinto, Jensen, Jiao, Karnik, Karnik, Komori, Kulke, Laplante, Loewith, Lovejoy, Luzi, Marinoni, Marion-Audibert, Mendel, Meric-Bernstam, Missiaglia, Mocellin, Panzuto, Papouchado, Passacantilli, Perren, Pàez-Ribes, Raymond, Sarbassov, Scoazec, Shah, Shi, Tang, Vinagre, Wang, Yang, Yao, Yuan, Zhang, Zhang   +64 more
core   +1 more source

Antibody drug conjugate: the “biological missile” for targeted cancer therapy

Signal Transduction and Targeted Therapy, 2022
Antibody–drug conjugate (ADC) is typically composed of a monoclonal antibody (mAbs) covalently attached to a cytotoxic drug via a chemical linker. It combines both the advantages of highly specific targeting ability and highly potent killing effect to ...
Zhiwen Fu, Shijun Li, Sifei Han, C. Shi, Yu Zhang   +4 more
semanticscholar   +1 more source

Current Targeted Therapy for Metastatic Colorectal Cancer

International Journal of Molecular Sciences, 2022
Colorectal cancer (CRC) is the third most common type of cancer and the second leading cause of cancer deaths worldwide. Surgery or surgery plus radiotherapy and/or chemotherapy for patients with metastatic CRC (mCRC) were accepted as the main ...
T. Ohishi, M. Kaneko, Y. Yoshida, A. Takashima, Y. Kato, M. Kawada   +5 more
semanticscholar   +1 more source

Oncolytic Reovirus-Mediated Recruitment of Early Innate Immune Responses Reverses Immunotherapy Resistance in Prostate Tumors

Molecular Therapy: Oncolytics, 2021
Prostate cancers are considered “cold” tumors characterized by minimal T cell infiltrates, absence of a type I interferon (IFN) signature, and the presence of immunosuppressive cells.
Nicola E. Annels, Guy R. Simpson, Mick Denyer, Mehreen Arif, Matt Coffey, Alan Melcher, Kevin Harrington, Richard Vile, Hardev Pandha   +8 more
doaj   +1 more source

Advances in targeted Alpha therapy for prostate cancer [PDF]

, 2019
BACKGROUND: Amongst therapeutic radiopharmaceuticals, targeted alpha therapy (TαT) can deliver potent and local radiation selectively to cancer cells as well as the tumor microenvironment and thereby control cancer while minimizing toxicity.
De Vincentis, G, Gerritsen, W, Gschwend, JE, Hacker, M, Lewington, V, O'Sullivan, JM, Oya, M, Pacilio, M, Parker, C, Sartor, O, Shore, N, Targeted Alpha Therapy Prostate Working Group   +11 more
core   +2 more sources

Tumor angiogenesis and anti-angiogenic therapy in malignant gliomas revisited [PDF]

, 2012
The cellular and molecular mechanisms of tumor angiogenesis and its prospects for anti-angiogenic cancer therapy are major issues in almost all current concepts of both cancer biology and targeted cancer therapy. Currently, (1) sprouting angiogenesis, (2)
Dumont, Daniel J., Plate, Karl H., Scholz, Alexander   +2 more
core   +1 more source

Acquired resistance to anti-MAPK targeted therapy confers an immune-evasive tumour microenvironment and cross-resistance to immunotherapy in melanoma

Nature Cancer, 2021
How targeted therapies and immunotherapies shape tumors, and thereby influence subsequent therapeutic responses, is poorly understood. In the present study, we show, in melanoma patients and mouse models, that when tumors relapse after targeted therapy ...
L. Haas, Anais Elewaut, C. Gerard, Christian Umkehrer, L. Leiendecker, M. Pedersen, Izabela Krecioch, David Hoffmann, M. Novatchkova, M. Kuttke, Tobias Neumann, I. D. da Silva, Harriet Witthock, M. Cuendet, S. Carotta, K. Harrington, J. Zuber, R. Scolyer, G. Long, J. Wilmott, O. Michielin, Sakari Vanharanta, T. Wiesner, A. Obenauf   +23 more
semanticscholar   +1 more source

Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer

Molecular Cancer, 2021
Colorectal cancer (CRC) is a heterogeneous disease at the cellular and molecular levels. Kirsten rat sarcoma (KRAS) is a commonly mutated oncogene in CRC, with mutations in approximately 40% of all CRC cases; its mutations result in constitutive ...
Gongmin Zhu, Lijiao Pei, Hongwei Xia, Qiulin Tang, Feng Bi   +4 more
doaj   +1 more source

What role does pyroptosis play in cancer?

Molecular Metabolism, 2022
Background: Pyroptosis has been attracting much attention recently. We have briefly compared its differences and similarities with other programmed deaths and the process of its study. With further exploration of the caspase family, including caspase-1/3/
Chen Huang, Jian Li, Chenliang Zhang
doaj   +1 more source